OXB Strengthens Financial Advisory Team with New Appointment
OXB (LSE: OXB), a leading cell and gene therapy contract development and manufacturing organization (CDMO), has announced an exciting new chapter in its journey. With the strategic appointment of Jefferies International Limited as its Joint Corporate Broker and Joint Financial Adviser, OXB aims to bolster its financial strategies and enhance its market position. This decision comes as OXB continues to innovate and lead in the rapidly advancing field of gene therapy, working closely with RBC Capital Markets for a synergistic approach to financial guidance.
About OXB and Its Mission
With a steadfast commitment to quality and innovation, OXB is dedicated to facilitating life-changing therapies for patients worldwide. The organization possesses over 25 years of expertise in the realm of viral vectors, which are essential in the development of cell and gene therapies. OXB collaborates with industry leaders in pharmaceuticals and biotechnology, delivering invaluable manufacturing and development services, particularly in viral vector technologies.
Innovative Technology Portfolio
OXB has made significant contributions to the field with its pioneering technologies, including the state-of-the-art Tetravecta™ system, a fourth-generation lentiviral vector system. This advanced technology, along with a dual plasmid system for adeno-associated virus (AAV) production, highlights OXB's commitment to staying ahead in the competitive landscape. The company also employs advanced suspension and perfusion processes that leverage process enhancers, ensuring high-quality production of viral vectors.
Collaboration and Expertise
OXB's extensive collaboration with leading pharmaceutical and biotechnology companies sets it apart as a trusted partner in the development and manufacturing of viral vectors. Their facilities in Oxford, UK, Lyon and Strasbourg, France, and near Boston, MA, enable OXB to provide world-class capabilities ranging from the earliest stages of drug development through to full commercialization. The intricate understanding of quality assurance, analytical methodologies, and regulatory affairs ensures that OXB meets the highest industry standards.
Enhancing Investor Relations
The appointment of Jefferies as a Joint Corporate Broker marks an important milestone in OXB's ongoing efforts to strengthen its investor relations and enhance overall communication with shareholders. The appointment reflects OXB’s strategic goal to increase transparency and improve resource allocation in alignment with global best practices.
Contact Information for Investor Inquiries
For queries regarding investment relations, stakeholders can reach out to Sophia Bolhassan, the Head of Investor Relations at OXB, at +44 (0) 1865 509 737 or via email at ir@oxb.com. Additionally, the ICR Healthcare team, including Mary-Jane Elliott, Angela Gray, and Davide Salvi, can be contacted through +44 (0)20 3709 5700 or oxb@icrhealthcare.com for further assistance.
OXB's Commitment to Quality
As a notable constituent of the FTSE4Good index, OXB is recognized for its dedication to ethical business practices and sustainability in the biotechnology sector. The emphasis on quality within the production processes not only ensures safety for patients but also supports OXB's mission to provide innovative solutions for global health challenges.
Future Growth Prospects
Looking ahead, OXB remains committed to expanding its capabilities and exploring new partnerships that will facilitate advancements in cancer therapy and other degenerative diseases. By leveraging its core strengths and integrating innovative practices, OXB is poised to maintain its leadership position in the burgeoning fields of cell and gene therapy.
Frequently Asked Questions
What is OXB known for?
OXB is a renowned CDMO focused on cell and gene therapy, specializing in viral vector development and manufacturing, committed to providing life-changing therapies.
Who has OXB appointed as its Joint Corporate Broker?
OXB has appointed Jefferies International Limited as its Joint Corporate Broker alongside RBC Capital Markets for enhanced financial advisory services.
What technologies does OXB offer?
OXB offers a range of technologies for viral vector manufacturing, including the Tetravecta™ system and advanced processes for AAV production.
Where are OXB's facilities located?
OXB operates bioprocessing and manufacturing facilities in Oxford, UK, as well as locations in France and near Boston, MA, US.
How can investors contact OXB?
Investors can contact Sophia Bolhassan, OXB's Head of Investor Relations, at +44 (0) 1865 509 737 or email ir@oxb.com for inquiries.
